Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases

Melanoma differentiation-associated protein 5 (MDA5) antibody-positive dermatomyositis (DM) displays unique cutaneous and pathologic features. We describe two cases of myositis-associated rapidly progressive interstitial lung disease (RP-ILD). The patients were two women from Kerala, India. Both patients had anti-MDA5 antibody-positive myositis. Both patients presented with RP-ILD without any clinical features of myositis and succumbed to their illness despite aggressive medical treatment. Anti-MDA5-antibody-positive DM is characterised by amyopathic disease with rapidly progressive and fatal ILD.

[1]  C. Bao,et al.  Mortality risk prediction in amyopathic dermatomyositis associated with interstitial lung disease: the FLAIR model. , 2020, Chest.

[2]  M. Strek,et al.  Recognition and Management of Myositis-Associated Rapidly Progressive Interstitial Lung Disease. , 2020, Chest.

[3]  Y. Shimojima,et al.  Effective Administration of Rituximab in Anti-MDA5 Antibody–Positive Dermatomyositis with Rapidly Progressive Interstitial Lung Disease and Refractory Cutaneous Involvement: A Case Report and Literature Review , 2017, Case reports in rheumatology.

[4]  N. Hagino,et al.  Dermatomyositis with Rapidly Progressive Interstitial Lung Disease Treated with Rituximab: A Report of 3 Cases in Japan , 2017, Internal medicine.

[5]  K. Masahiko,et al.  A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment , 2017, Modern rheumatology.

[6]  H. Harigae,et al.  Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis , 2016, Modern rheumatology.

[7]  M. Strek,et al.  Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. , 2016, Pulmonary pharmacology & therapeutics.

[8]  B. Ye,et al.  The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. , 2015 .

[9]  Ø. Molberg,et al.  Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. , 2015, Rheumatology.

[10]  M. Aringer,et al.  Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. , 2014, Rheumatology.

[11]  Andriy I. Bandos,et al.  Predictors of Clinical Improvement in Rituximab‐Treated Refractory Adult and Juvenile Dermatomyositis and Adult Polymyositis , 2014, Arthritis & rheumatology.

[12]  C. Prins,et al.  Response of Mucocutaneous Lesions to Rituximab in a Case of Melanoma Differentiation Antigen 5-Related Dermatomyositis , 2013, Dermatology.

[13]  H. Yamanaka,et al.  Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. , 2012, Rheumatology.

[14]  J. Ménard,et al.  Rituximab therapy for refractory interstitial lung disease related to antisynthetase syndrome. , 2012, Respiratory medicine.

[15]  H. Yamanaka,et al.  Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. , 2010, Rheumatology.

[16]  J. Gran,et al.  Rituximab treatment of the anti-synthetase syndrome: a retrospective case series. , 2009, Rheumatology.

[17]  P. Gerami,et al.  A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. , 2006, Journal of the American Academy of Dermatology.

[18]  T. Nishikawa,et al.  Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. , 2005, Arthritis and rheumatism.

[19]  T. Kurita,et al.  The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. , 2015, Rheumatology.